MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$166,458
Net Income
-$4,276,377
Net Profit Margin
-2569.04%
EPS
-$0.29
Unit: Dollar
Revenue Breakdown
Product Talicia
Product Sancuso
Product Vibativ
Others
Revenue Breakdown
General and administrative
Research and development
Amortization
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net revenues from continuing operations
166,458
9,131,317
15,816,928.5*
8,292,362
Cost of products sold
-
1,933,889
2,166,983.5*
988,760
Selling and marketing
-
5,064,875
6,111,936*
4,433,831
Research and development
772,162
1,458,436
1,483,849*
1,253,367
General and administrative
2,547,606
2,554,475
3,776,427*
2,572,066
Amortization
7,151
1,248,934
1,010,534*
1,009,598
Total costs and expenses
3,326,919
12,260,609
14,549,729.5*
10,257,622
Operating gain
-3,160,461
-3,129,292
1,267,199*
-1,965,260
Interest income
60,884
78,031
88,140*
131,583
Other income - gain on insurance proceeds
-
-
0*
0
Interest expense
724
85,839
167,121*
109,699
Income (loss) before income taxes
-
-3,137,100
1,188,218*
-
Loss before income taxes
-3,100,301
-
-
-1,943,376
Income tax expense
3,870
3,871
23,244.5*
5,670
Net loss from continuing operations
-3,104,171
-
-
-
Co-commercialization investment loss
-
-146,080
-3,305*
-
Net income (loss) from discontinued operations
-1,170,259
-
-
-
Net income (gain)
-4,274,430
-3,287,051
1,161,668.5*
-1,949,046
Net income (loss) at subsidiary attributable to noncontrolling interests
1,947
2,588
-24,459.5*
-8,282
Net income (gain) attributable to common shareholders
-4,276,377
-3,289,639
1,186,128
-1,940,764
Basic EPS
-0.29
-0.22
0.081
-0.13
Diluted EPS
-0.29
-0.22
0.081
-0.13
Basic Average Shares
14,981,607
14,960,210
14,644,727
14,958,534
Diluted Average Shares
14,981,607
14,960,210
14,644,727
14,958,534
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net income (gain)
attributable to common...
-$4,276,377
(-477.31%↓ Y/Y)
Net income (gain)
-$4,274,430
(-481.39%↓ Y/Y)
Net income (loss) at
subsidiary attributable to...
$1,947
(-64.81%↓ Y/Y)
Net loss from
continuing operations
-$3,104,171
Net income (loss)
from discontinued...
-$1,170,259
Product Talicia
$2,349,890
Product Sancuso
$1,816,737
(-41.75%↓ Y/Y)
Product Vibativ
$1,738,887
(-35.64%↓ Y/Y)
Product Caldolor
$1,474,288
(-7.18%↓ Y/Y)
Product Kristalose
$1,061,442
(-61.46%↓ Y/Y)
Product Other
$221,534
(-55.01%↓ Y/Y)
Product Acetadote
$136,661
(-29.39%↓ Y/Y)
Revenues, including
adjustments-Product Redi Trex
$1,802
(-44.45%↓ Y/Y)
Loss before income
taxes
-$3,100,301
(-324.97%↓ Y/Y)
Income tax expense
$3,870
(-31.76%↓ Y/Y)
Interest income
$60,884
(-52.24%↓ Y/Y)
Revenues
$8,801,241
Operating gain
-$3,160,461
(-322.82%↓ Y/Y)
Net revenues from
continuing operations
$166,458
(-98.46%↓ Y/Y)
Interest expense
$724
(-99.34%↓ Y/Y)
Net revenues
-$8,634,783
(-179.68%↓ Y/Y)
Total costs and
expenses
$3,326,919
(-71.28%↓ Y/Y)
General and
administrative
$2,547,606
(-11.39%↓ Y/Y)
Research and development
$772,162
(-47.41%↓ Y/Y)
Amortization
$7,151
(-99.29%↓ Y/Y)
Buy us a coffee
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)